Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01470183 · ClinicalTrials.gov registry record
Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients
A clinical trial, sponsored by Columbia University.
- Completed
- Registry status
- 46
- Enrollment target
NCT01470183: Completed study, sponsored by Columbia University.
NCT01470183 is a clinical trial that has completed, run by Columbia University. The registered enrollment target is 46 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01470183 has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- 46 participants
- Enrollment target
Study Summary
This is an exploratory study. No formal hypothesis will be tested. The objectives of this study are to follow Lupus Nephritis patients over a period of 12 months to: * Establish the baseline biomarker characteristics of patients * Determine the variability of biomarker measures over time * Correlate biomarkers with disease phenotype
Primary Outcome
Whole blood samples will be collected from all subjects for the analysis of mRNA expression of genes relevant to lupus nephritis (IFNa signature, TNFa/TNFa receptor families, defensins, TH1, TH17 related pathway genes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2011-10 |
| Est. Completion | 2013-02 |
What the finished NCT01470183 record still lists
NCT01470183 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 46 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01470183 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01470183 about?
NCT01470183 is a clinical study titled "Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients". This is an exploratory study. No formal hypothesis will be tested. The objectives of this study are to follow Lupus Nephritis patients over a period of 12 months to: * Establish the baseline biomarker characteristics of patients * Determine the variability of biomarker measures over time * Correla...
What is the current status of trial NCT01470183?
This trial is currently completed. The enrollment target is 46 participants. The study started on 2011-10. Estimated completion is 2013-02.
Who is sponsoring clinical trial NCT01470183?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia